Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) improved cancer therapy by inducing a higher immune system activity. This effect can cause rheumatic immune-related adverse events (rh-irAEs), which have not yet been extensively studied. METHODS: We analysed 437 patients between 2014 and 2019, treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Verspohl, Sophia H., Holderried, Tobias, Behning, Charlotte, Brossart, Peter, Schäfer, Valentin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047846/
https://www.ncbi.nlm.nih.gov/pubmed/33912248
http://dx.doi.org/10.1177/1759720X211006963

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047846/
https://www.ncbi.nlm.nih.gov/pubmed/33912248
http://dx.doi.org/10.1177/1759720X211006963

Ejemplares similares